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Background: The purpose of this research was to study the gene expression of interleukin-6 (IL-6), tumor necrosis factor-α
(TNF-α), nuclear factor kappa B (NF-κB), vascular endothelial growth factor A (VEGF-A) and adiponectin (AdipoQ) genes in
the visceral (omental, mesenteric) and subcutaneous adipose tissue depots in metabolic syndrome (MS).
We studied 23 women with MS, with a mean age of 50.7 ± 4.5 years and mean body mass index (BMI) of 45.6 ± 9.8 kg/m2.
The control group included 10 women, with a mean age of 40.6 ± 8.7 years and normal BMI (22.3 ± 3.7 kg/m2). The gene
expression levels in the omental (OAT), mesenteric (MAT) and subcutaneous (SAT) adipose tissues were assessed by
quantitative real-time PCR.
Findings: Increased gene expression levels of IL-6 and TNF-α were detected in MAT in patients with MS, compared
with the control group (p < 0.05 and p < 0.005, respectively). Significant positive correlations were observed between
IL-6 mRNA expression levels in OAT and the content of CD14 + cells in the peripheral blood (r = 0.55, p < 0.05), as well
as between NF-κB and VEGF-A mRNA levels in OAT (r = 0.43, p < 0.05) in patients with MS. The AdipoQ gene expression
levels in OAT were significantly decreased in women with MS compared with the control group (p < 0.05). In addition,
there were inverse correlations between AdipoQ gene levels in MAT and serum CRP levels (r = −0.63, p < 0.05), as well
as between AdipoQ gene levels in MAT and serum IL-6 levels (r = −0.46, p < 0.05).
Conclusion: These data demonstrate that proinflammatory gene expression of MAT in women with MS was increased
compared with the control group. The AdipoQ gene expression levels in OAT were significantly decreased in women
with MS compared with the control group.
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Significant differences exist between fat depots in relation
to the complications associated with MS. MS is a risk fac-
tor for systemic inflammation, cardiovascular diseases and
thrombosis [1], and it has been associated with increased
levels of visceral fat, insulin resistance, arterial hyperten-
sion, lipid and carbohydrate metabolism disorders [2]. Ap-
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more than 80% have diabetes [3].
Adipose tissue produces adipokines, hormones and cyto-
kines and contains various cells, such as adipocytes, preadi-
pocytes, vascular cells, endotheliocytes, lymphocytes and
macrophages expressing CD14 receptors [4-7]. In obesity,
the increased production of inflammation mediators in the
adipose tissue, liver, pancreas and skeletal muscles causes
subclinical metabolic inflammation [5,8,9]. This inflamma-
tion affects the metabolic and secretory function of adipose
tissue and plays a leading role in the development of obesity
accompanying MS, type 2 diabetes mellitus and atheroscler-
osis [10-12]. The main source of proinflammatory mediatorsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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inflammation also involves cell infiltration, fibrosis devel-
opment, impaired microcirculation, enhanced adipokines
and proinflammatory cytokines in the VAT (visceral adi-
pose tissue) and increased levels of non-specific inflamma-
tory biomarkers, such as CRP (C-reactive protein),
fibrinogen, and leukocytes in the blood [13-15]. The level
of inflammatory response strongly correlates with the de-
gree of obesity [16].
Visceral and subcutaneous adipocytes might have differ-
ent properties in the production of bioactive molecules. A
high rate of IL-6 production in OAT suggests that IL-6 is
an important regulator of adipose tissue metabolism. The
gene expression profiles are different between visceral and
subcutaneous fat depots [17]. However, in other studies,
TNF-α mRNA expression levels were shown to be similar
in these two sites [18].
There are also sex differences in fat distribution between
men and women that may contribute to insulin resistance
and obesity-related metabolic abnormalities [19]. Men ac-
cumulate more fat in the central (abdominal) area (mostly
in visceral depots), while overweight women have demon-
strated a tendency to accumulate subcutaneous fat [20].
Despres et al. showed a positive correlation between blood
glucose levels and visceral adipose tissue in obese women
[21]. Moreover, in addition to sex-specific patterns, age
may play an important role in risk of MS and its complica-
tions [22].
It is worth noting that the visceral fat is composed of
omental and, to a lesser degree, mesenteric adipose tissue.
The physiological differences in the metabolism and gene
expression patterns between MAT and OAT are still
unknown. Accordingly, the detailed study of adipose tissue-
specific proinflammatory cytokines and AdipoQ gene
expression profiles is important for the estimation of the
contributions of these two types of VAT to chronic adipose
tissue inflammation in MS.
Materials and methods
Subjects
We studied the different adipose tissue depots taken
from 33 patients during routine laparoscopic surgery.
The patients were divided into two groups according
to their BMI.
The subjects (n = 23) were women with MS. The diag-
nosis of MS was defined according to the International
Diabetes Federation (IDF) criteria (2005) [23]. The mean
age of the study population was 50.7 ± 4.5 years and the
mean BMI 45.6 ± 9.8 kg/m2. The control group included
10 women with a mean age of 40.6 ± 8.7 years and normal
BMI (the mean BMI was 22.3 ± 3.7 kg/m2). All subjects
gave informed consent, and the study was approved
by the Local Ethics Committee of the Baltic Federal
University.Blood
Blood was obtained by puncture of the cubital vein and
taken in the morning after 12 hours of fasting. The blood
was collected in Vacuette vacuum tubes with serum clot
activator or EDTA for plasma preparation.
Determination of CD14 + сells in peripheral blood
The determination of cells positive for the surface marker
CD1 in the peripheral blood was performed by MACS
Quant laser flow cytometry (Miltenyi Biotec, Germany)
using monoclonal antibodies (MABs) with fluorescent
labels FITC (Fluorescein isothiocyanate) and R-PE
(R-Phycoerythrin) (Abcam, UK).
Determination of the serum concentrations of IL-6,
TNF-α and VEGF
The serum concentrations of IL-6, TNF-α and VEGF
were determined by ELISA (Vector Best, Russia) using
DS2 automated ELISA analyzer (Dynex Technologies,
USA), according to the manufacturer’s instructions.
Determination of plasma adiponectin concentration
Plasma adiponectin concentration was assessed by flow
cytometry on a double beam laser automated analyser (Bio-
Plex Protein Assay System, Bio-Rad, USA) using commer-
cial test kits (Bio-PlexPro Human Diabetes Adipsin and
Adiponectin Assays, Bio-Rad, USA), according to the
manufacturer's protocol.
Determination of C-reactive protein in serum
The serum concentration of CRP was determined using
a reagent kit (CRP FS, DiaSys, Germany).
Tissue
OAT, MAT and SAT were obtained during laparoscopic
surgery. The tissue samples were placed into RNAlater
RNA Stabilisation Reagent (QIAGEN, Germany), ac-
cording to the manufacturer’s protocol, to prevent RNA
degradation. Total RNA isolation was performed using
the ExtractRNA reagent kit (Eurogene, Russia). The
quantitative determination of RNA concentration was
performed using a NanoVue Plus spectrophotometer
(GE Healthcare, USA). The reverse transcription of total
RNA samples was performed using MMLV RT (Moloney
Murine Leukemia Virus Reverse Transcriptase) reagent
kit (Eurogene, Russia), according to the manufacturer’s
protocol. OligodT10–primer, 20 μM, was used as a seed
primer. The assessment of relative gene expression was
based on real-time quantitative PCR using qPCRmix-HS
SYBR reagents (Eurogene, Russia). A total of 4 μl of the
complimentary DNA was used as a template.
β2-Microglobulin (B2M) was used as a normalisation
gene. The following primers were used in the study: IL-
6 - for 5'-cct-tcg-gtc-cag-ttg-cct-tc-3', IL-6 - rev 5'- gtg-
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variants - for 5'-caa-cat-gcc-cat-tcg-ctt-t3', AdipoQ - rev
5'- gga-ggc-ctg-gtc-cac-att-at-3'; TNF-α - for 5'-ccc-tca-
acc-tct-tct-ggc-tca-a-3', TNF-α - rev 5'-cca-ggt-ttc-gaa-
gtg-gtg-gtc-t-3'; NF-κB - for 5'-gtg-gtg-cct-cac-tgc-taa-ct-3',
NF-κB - rev 5'-gga-tgc-act-tca-gct-tct-gt-3'; VEGF-A - for
5'-gtt-ttg-gga-aca-ccg-aca-aac-c-3', VEGF-A - rev 5'-cgg-tgt-
cct-cat-ccc-tgt-acc-t-3'; B2M - for 5'-cac-ccc-cac-tga-aaa-
aga-tg-3', B2M - rev 5'- ata-tta-aaa-agc-aag-caa-gca-gaa-3'.
PCR analysis
The PCR reaction was repeated three times using the Light
Cycler 480 Real-Time PCR amplifier (Roche, Switzerland).
The amplification protocol was as follows: primary denatur-
ation – 5 minutes at 95°С; amplification cycle (х 50): de-
naturation – 20 sec. at 95°С; primer annealing - 30 sec. at
60°С; elongation - 60 sec. at 72°С; post-incubation - 5 mi-
nutes at 72°С. The PCR results were analysed using the
Second Derivative Maximum Method.
Statistical analysis
Statistical analysis was performed using IBM SPSS Sta-
tistics 20. The nonparametric Mann–Whitney U test
was used to determine the significance of differences be-
tween independent groups. The results were considered
statistically significant at the 0.05 significance level. Cor-
relation analyses were performed by calculating the
Spearman rank correlation coefficient (r) to assess the
relationships between the studied parameters.
Statistical analysis of PCR data was performed using the
specialised software programme REST 2009 v.2.0.13. The
calculation of relative gene expression in this software isFigure 1 Relative expression of 5 target mRNAs in OAT, MAT and SAT
expression ratio is the fold change between the sample expression and the
real-time PCR assay in adipose biopsies. The gene expression was quantifie
**P < 0.005. OAT – omental adipose tissue; MAT - mesenteric adipose tissuebased on Pfafflʼs formula [24]. The algorithms for the statis-
tical analysis program have been validated for application to
the specific randomisation test designed to interpret the
real-time quantitative PCR data. The statistical significance
of the differences in expression levels between the control
and studied groups was evaluated for each gene by random-
isation tests and was based on the mean Cp values. Differ-
ences were considered significant at a significance level of
p < 0.05.
Results
A 3-fold decrease in AdipoQ gene expression levels in the
OAT was observed in patients with MS compared with the
control group (p < 0.05) (Figure 1). There were no significant
differences in IL-6, TNF-α, NF-κB and VEGF-A gene ex-
pression levels in the OAT of patients with MS compared to
the control group. There were no significant differences in
the expression levels of the studied genes in SAT in the pa-
tients with MS compared to the control group.
The IL-6 gene expression levels were 5-fold greater in
women with MS than in the control group (p < 0.05)
(Figure 1). The TNF-α gene expression levels were 4-fold
greater in women with MS than in the control group (p <
0.005) (Figure 1). There were no significant differences in
the AdipoQ, VEGF-A and NF-κB gene expression levels in
MAT in the MS group compared to the control group.
The IL-6 and TNF-α serum levels were significantly
higher (4.9 (3.7-6.5) and 28.3 (15.3-43.5) pg/ml) in MS
than in the control group (1.3(0.5-1.9) and 3.3 (2.7-4.5))
(p < 0.05 and p <0.05, respectively) (Table 1). Serum VEGF
levels were comparable to the control group and were 180
(160–320) pg/ml (p > 0.05). The plasma adiponectinin MS (n = 23 women) vs. the control group (n = 10 women). The
control groups. The specific mRNAs were assessed by quantitative
d by normalization to reference gene β2-microglobulin. *P < 0.05.
; SAT - subcutaneous adipose tissue.
Figure 2 The percentage of CD14+ сells in peripheral blood in
patients with MS (23 women) and the control group (10 women).
Litvinova et al. Diabetology & Metabolic Syndrome 2014, 6:137 Page 4 of 9
http://www.dmsjournal.com/content/6/1/137concentration was significantly lower in MS (2.0 (1.4-3.1)
pg/ml) than in the control group (3.6 (2.7-4.2) pg/ml).
We demonstrated a significant increase in the content
of CD14 + cells in the peripheral blood in patients with
MS (8.9 (8.2-9.8) compared with the control group (4.8
(4.0-5.4)) (p < 0.05) (Figure 2). The serum CRP concentra-
tion in patients with MS was 10.6 (9.9 - 13.4) mg/l, ex-
ceeding the value of the control group, which was on
average 5-fold (p = 0.001) (Figure 3).
There were positive correlations between IL-6 gene ex-
pression levels in OAT and BMI (r = 0.46, p < 0.05) and
between serum TNF-α levels and BMI in patients with
MS (r = 0.82, p < 0.05) (Figure 4). The serum TNF-α levels
correlated with TNF-α gene expression in OAT (r = 0.42,
p <0.05) (Figure 5). Significant correlations were observed
between IL-6 gene expression levels in SAT and TNF-α
gene expression in SAT (r = 0.85, p < 0.05), as well as
TNF-α gene expression in SAT and VEGF-A gene expres-
sion levels in SAT (r = 0.93, p < 0.05) (Figure 6).
We found that in MAT, the VEGF-A gene expression
levels correlated with NF-κB gene expression levels (r = 0.43,
p < 0.05) (Figure 7). Moreover, in OAT, we revealed a posi-
tive correlation between VEGF-A gene expression levels and
AdipoQ mRNA expression (r = 0.77, p < 0.05), as well as
serum VEGF levels and AdipoQ gene expression levels
(r = 0.42, p < 0.05) (Figure 5). We also observed a positive
correlation between AdipoQ gene expression levels in OAT
and its plasma levels (r = 0.49, p < 0.05) (Figure 5).
We demonstrated a negative correlation between AdipoQ
gene expression in MAT and serum IL-6 levels (r = −0.46,
p < 0.05), which indicates the development of inflammation
in MS (Figure 7). We also showed a negative correlation
between the level of AdipoQ gene expression in MAT and
the serum CRP levels (r = −0.63, p < 0.05) (Figure 7).
We found positive correlations between the number of
CD14 + cells and IL-6 gene expression levels in OAT
(r = 0.55, p < 0.05) (Figure 5). Of interest, we also dem-
onstrated a positive correlation between the number of
CD14+ cells in the peripheral blood and BMI (r = 0.46,
p < 0.05) (Figure 4).
Discussion and conclusion
The adipocytes, preadipocytes and macrophages infiltrating
adipose tissue in obesity are sources of proinflammatoryTable 1 Serum levels of proinflammatory factors (CRP, IL-6, T
(Me(Q1-Q3)) in patients with MS (23 women) and the control
Variable Metabolic syndro
IL-6 (pg/ml) 4.9 (3.74-6.55) p < 0
TNF-α (pg/ml) 28.28 (15.26-43.49)
VEGF (pg/ml) 180 (160–320) p > 0
Adiponectin (μg/ml) 2.0 (1.4 – 3.1) p < 0
p - significance of differences as compared to the control group.cytokines [10,25,26]. Cytokine production causes chronic
inflammation [13], and the activation of proinflammatory
mechanisms correlates with insulin resistance and athero-
sclerosis [10,11,27]. The VAT plays important roles in the
development of type 2 diabetes, atherosclerosis and cardio-
vascular diseases [7,10,11].
VAT is, to a large extent, represented by hypertrophied
adipocytes with a high degree of sensitivity to hormonal
effects and is therefore more metabolically active than
subcutaneous or extraperitoneal fat [28]. IL-6 and TNF-
α are predictors of vascular complications of diabetes in
obesity and play a leading role in atherosclerosis and the
development of insulin resistance [10,29]. Increased IL-6
gene expression in adipose tissue leads to an increase in
IL-6 serum levels, which positively correlates with BMI
[5,6,30]. The concentrations of IL-6 and TNF-α in the
VAT are higher than its circulating levels [31,32]. Our
results demonstrate, for the first time, an increase in IL-
6 and TNF-α gene expression, specifically in MAT and
VAT, in patients with MS compared with the control
group.
NF-κB is a transcription factor that influences the ex-
pression of various genes involved in immune and inflam-
matory responses [33]. The NF-κB signalling pathwayNF-α, VEGF) and adiponectin plasma concentrations
group (10 women)
me (n = 23) Control group (n = 10)
.05 1.35 (0.55-1.95)
p < 0.05 3.30 (2.70-4.55)
.05 172 (156–290)
.05 3.6 (2.7–4.2)
Figure 3 The content of CRP in serum in patients with MS
(23 women) and the control group (10 women).
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(HIF-1α) leads to the increased production of VEGF by
different cells [34,35]. VEGF-A is a key molecule in vascu-
logenesis, angiogenesis, vascular permeability and tissue
remodelling [36,37].
In adipose tissue, hypoxia plays an important role in
the activation of the transcription factors NF-κB and
HIF-1α in adipocytes and macrophages [36]. The proin-
flammatory cytokines can act as inducers of NF-κB acti-
vation in adipose tissue inflammation [34,38]. To prove
the influence of NF-κB gene expression on the increased
levels of proinflammatory cytokines and NF-κB activa-
tion in adipose tissue, we will need to perform immuno-
histochemistry analysis of NF-κB nuclear localisation on
tissue sections in the future.
The trend of increased VEGF-A gene expression in
OAT in patients with MS compared with the controlFigure 4 Correlation between serum BMI and TNF-α levels (a), conten
in OAT (c). The gene expression levels were assessed by quantitative real-t
(10 women). The Pearson correlation coefficients (r) are shown on the figugroup might be associated with the activation of the NF-
κB signalling pathway [26]. The overexpression of the
VEGF-A gene has a protective effect against adipose tissue
inflammation by attracting M2-macrophages to the fat
depot, thereby maintaining the inflammatory microenvir-
onment [39].
The literature relating to serum VEGF concentrations
and its gene expression levels in adipose tissue in obesity
are contradictory [40-42]. Some studies have shown that
the VEGF serum levels were significantly correlated with
BMI and depended on its gene expression in VAT [40,41].
However, other authors have reported decreased VEGF-A
gene expression in adipose tissue in obesity [42]. The de-
crease in VEGF-A production in adipose tissue in patients
with type 2 diabetes may indicate a protective role of
VEGF-A against insulin resistance induced by obesity
[38,39,42,43].
Adiponectin is a key mediator synthesised in adipose
tissue. Adiponectin improves insulin sensitivity and en-
hances insulin effects in peripheral tissues, particularly
in the muscle, liver and adipose tissues. Decreased secre-
tion of adiponectin in obesity is one of the leading fac-
tors involved in the development of insulin resistance
[44,45].
We demonstrated significant changes in AdipoQ gene
expression levels in OAT in patients with MS compared
with the control group. According to previous studies, a
higher level of secretion was observed in SAT than in
VAT [17,45]. Another study suggested that AdipoQ gene
expression in SAT exhibited an inverse correlation with
plasma adiponectin levels [46]. The decrease of plasma
adiponectin levels in patients with MS confirmed the
data in the existing literature [17,47].
The expression of CD14 in macrophages and mono-
cytes participates in activation via a mechanism
mediated by Toll-like receptor-4 and a receptor for
complexes of lipopolysaccharide (LPS) and LPS-binding
protein [48,49]. The presence of positive correlationst of CD14 + cells in the peripheral blood (b), IL-6 gene expression
ime PCR assay in OAT from 23 women with MS and the control group
re and the P value if statistically significant with a P < 0.05.
Figure 5 Correlations between AdipoQ α gene expression in OAT and plasma adiponectin levels (a),serum VEGF levels (b), VEGF-A gene
expression in OAT (c), between and TNF-α gene expression in OAT and serum TNF-α levels (d), IL-6 gene expression in OAT and content of
CD14 + cells in the peripheral blood (e). The gene expression levels were assessed by quantitative real-time PCR assay in OAT from 23 women with
MS and the control group (10 women). The Pearson correlation coefficients (r) are shown on the figure and the P value if statistically significant with a
P < 0.05.
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expression levels in OAT reflects the fact that an in-
crease in blood CD14 + cells is mediated by the in-
creased production of proinflammatory cytokines in
adipose tissue [10,11].Figure 6 Correlation between TNF-α gene expression in SAT and IL-6
The gene expression levels were assessed by quantitative real-time PCR ass
The Pearson correlation coefficients (r) are shown on the figure and the PSerum CRP level is an integral marker of metabolic dis-
orders [50]. In our study, serum CRP levels were increased
in patients with MS compared with the control group. Ac-
cording to the literature, elevated CRP serum levels in pa-
tients with MS were mediated by the ability of adiposegeneexpression in SAT (a), VEGF-A gene expression in SAT (b).
ay in SAT from 23 women with MS and the control group (10 women).
value if statistically significant with a P < 0.05.
Figure 7 Correlations between serum AdipoQ gene expression in MAT and serum IL-6 levels (a), serum CRP levels (b), between VEGF-A
gene expression in MAT and NF-κB gene expression in MAT (c). The gene expression levels were assessed by quantitative real-time PCR assay in
MAT from 23 women with MS and the control group (10 women). The Pearson correlation coefficients (r) are shown on the figure and the P value if
statistically significant with a P < 0.05.
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mediators (IL-6, TNF-α and PAI-1) [51], which can stimu-
late CRP production by liver cells [52].
In fact, in a number of studies, adiponectin concentra-
tions have been found to be inversely associated with
systemic inflammation and increased concentrations of
high-sensitive C-reactive protein (hs-CRP) [53]. Previous
studies have indicated that plasma hs-CRP levels were
negatively correlated with plasma adiponectin levels in pa-
tients with coronary artery disease [53]. The adiponectin/
CRP ratio was significantly lower in MS subjects than in
control subjects in another study [54]. It has been previ-
ously shown that adiponectin reduces CRP synthesis and
secretion from human aortic endothelial cells under hyper-
glycaemia via the upregulation of AMP kinase and the
downregulation of NF-κB [55].
The inverse correlation between MAT AdipoQ gene ex-
pression and serum CRP levels may indicate the initiation
of proinflammatory processes in MAT under the influence
of CRP in MS and obesity-related diseases. Interestingly,
this significant inverse correlation was observed between
CRP and adiponectin mRNA levels in human SAT [53].
IL-6 is one of the inducers of CRP synthesis and secre-
tion by adipocytes in MS [56]. It also explains the nega-
tive correlation between MAT AdipoQ gene expression
and serum IL-6 levels in women with MS.
It has been concluded in previous studies that the mes-
enteric adipose tissue has the highest levels of gene ex-
pression [57]. Our study identified a significant increase in
IL-6 and TNF-α gene expression levels in the mesenteric
adipose tissue and indicates an enhanced proinflammatory
process in MS. Accordingly, a recent study has demon-
strated a direct relationship between the thickness of the
mesenteric adipose tissue and intima-media thickness
[58]. Our results confirmed the data obtained in a study of
mesenteric fat thickness, indicating the dependence of the
risk of MS on the amount of MAT [59].Thus, we have established that the proinflammatory
properties of adipose tissue depend on its localisation in
women. We have showed a significant increase in the gene
expression levels of IL-6 and TNF-α in MATand a decrease
in AdipoQ gene expression levels in OAT in women with
MS compared with the control group. These results allow
us to conclude that VAT is more involved in chronic adi-
pose tissue inflammation than SAT. We demonstrated that
MAT is more inflammatory than OAT and SAT in women
with MS. The interrelation with key proinflammatory serum
markers, namely, the NF-κB and VEGF-A mRNA levels,
confirm that all three types of fat depots participate in sys-
temic inflammation in women with MS. Understanding the
molecular mechanisms of energy homeostasis disorders will
allow personalised targeted therapy based on the molecular
signature of inflammatory markers of the adipose tissue.
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